X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3385) 3385
Publication (337) 337
Book Review (72) 72
Book Chapter (27) 27
Dissertation (5) 5
Book / eBook (4) 4
Conference Proceeding (4) 4
Magazine Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (2419) 2419
humans (2348) 2348
index medicus (1625) 1625
aromatase inhibitors (1331) 1331
breast neoplasms - drug therapy (1271) 1271
oncology (1112) 1112
breast cancer (1072) 1072
animals (899) 899
postmenopausal women (850) 850
middle aged (768) 768
tamoxifen (761) 761
male (677) 677
aromatase inhibitors - therapeutic use (652) 652
adult (638) 638
aromatase inhibitors - administration & dosage (631) 631
estrogen (626) 626
aromatase (619) 619
aged (608) 608
letrozole (589) 589
aromatase inhibitor (582) 582
triazoles - administration & dosage (523) 523
nitriles - administration & dosage (513) 513
breast neoplasms - pathology (502) 502
endocrinology & metabolism (484) 484
cancer (475) 475
treatment outcome (472) 472
anastrozole (466) 466
postmenopause (465) 465
obstetrics & gynecology (417) 417
antineoplastic agents, hormonal - therapeutic use (404) 404
women (400) 400
endocrine therapy (396) 396
aromatase inhibitors - adverse effects (360) 360
care and treatment (357) 357
triazoles - therapeutic use (355) 355
randomized-trial (354) 354
nitriles - therapeutic use (351) 351
tamoxifen - therapeutic use (342) 342
tamoxifen - administration & dosage (340) 340
research (338) 338
chemotherapy, adjuvant (337) 337
rats (330) 330
antineoplastic agents, hormonal - administration & dosage (323) 323
estradiol (310) 310
antineoplastic combined chemotherapy protocols - therapeutic use (294) 294
aromatase inhibitors - pharmacology (287) 287
health aspects (285) 285
pharmacology & pharmacy (285) 285
aromatase - metabolism (282) 282
breast neoplasms - metabolism (263) 263
estradiol - blood (262) 262
pregnancy (259) 259
drug administration schedule (258) 258
aged, 80 and over (256) 256
therapy (254) 254
testosterone (253) 253
drug therapy (250) 250
chemotherapy (246) 246
reproductive biology (244) 244
triazoles - pharmacology (235) 235
expression (231) 231
exemestane (228) 228
analysis (227) 227
medicine & public health (223) 223
disease-free survival (215) 215
dose-response relationship, drug (215) 215
antineoplastic agents - therapeutic use (212) 212
breast-cancer (212) 212
mice (210) 210
nitriles - pharmacology (210) 210
nitriles - adverse effects (207) 207
triazoles - adverse effects (206) 206
antineoplastic agents, hormonal - adverse effects (200) 200
time factors (183) 183
estrogens (181) 181
article (180) 180
risk factors (180) 180
receptors, estrogen - metabolism (178) 178
double-blind (177) 177
breast neoplasms - mortality (176) 176
menopause (176) 176
clinical trials as topic (166) 166
aromatase - genetics (165) 165
randomized controlled trials as topic (164) 164
neoplasm staging (161) 161
biochemistry & molecular biology (158) 158
clinical trials (154) 154
double-blind method (154) 154
hormones (154) 154
adjuvant treatment (152) 152
testosterone - blood (150) 150
androgens (149) 149
estradiol - pharmacology (146) 146
antineoplastic agents - administration & dosage (143) 143
trial (143) 143
administration, oral (141) 141
abridged index medicus (140) 140
estrogen-receptor (140) 140
ovulation induction - methods (139) 139
neoplasms, hormone-dependent - drug therapy (137) 137
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3292) 3292
Japanese (37) 37
German (22) 22
French (18) 18
Russian (10) 10
Italian (9) 9
Hungarian (7) 7
Chinese (5) 5
Danish (3) 3
Korean (3) 3
Polish (3) 3
Bulgarian (2) 2
Dutch (2) 2
Norwegian (2) 2
Portuguese (2) 2
Spanish (2) 2
Swedish (2) 2
Finnish (1) 1
Hebrew (1) 1
Romanian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 25 - 35
Summary Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EXEMESTANE | ONCOLOGY | CELL-CYCLE | POSTMENOPAUSAL WOMEN | HER2 | PLUS | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Triazoles - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Molecular Targeted Therapy | North America | Nitriles - administration & dosage | Breast Neoplasms - enzymology | Time Factors | Postmenopause | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Republic of Korea | Aromatase Inhibitors - administration & dosage | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Europe | Proportional Hazards Models | Cyclin-Dependent Kinase Inhibitor p16 - genetics | Treatment Outcome | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Cyclin D1 - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | South Africa | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Care and treatment | Oncology, Experimental | Estrogen | Breast cancer | Research | Antineoplastic agents | Phosphotransferases | Cancer
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 01/2017, Volume 23, Issue 1, pp. 26 - 34
Purpose: Alpelisib, a selective oral inhibitor of the class I PI3K catalytic subunit p110 alpha, has shown synergistic antitumor activity with endocrine... 
ACTIVATION | NVP-BYL719 | PIK3CA MUTATIONS | PI3K | ONCOLOGY | PHOSPHATIDYLINOSITOL 3-KINASE | GROWTH | ESTROGEN DEPRIVATION | RESISTANCE | ALPHA | TUMORS | Triazoles - administration & dosage | Receptors, Estrogen - metabolism | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Thiazoles - administration & dosage | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Biomarkers, Tumor | Breast Neoplasms - metabolism | Nitriles - administration & dosage | Neoplasm Metastasis | DNA Mutational Analysis | Adult | Female | Aromatase Inhibitors - administration & dosage | Receptors, Estrogen - genetics | In Situ Hybridization, Fluorescence | Treatment Outcome | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Maximum Tolerated Dose | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Cell Line, Tumor | Aged | Mutation | Neoplasm Staging | Letrozole | Therapy | Toxicity | p53 Protein | Exanthema | Clinical trials | Metastasis | K-Ras protein | Metastases | Gene sequencing | Anticancer properties | Hyperglycemia | Safety engineering | Catalysis | Fibroblast growth factor receptor 1 | Deoxyribonucleic acid--DNA | Diarrhea | Endocrine therapy | Fatigue | Nausea | Breast cancer | Patients | ErbB-2 protein | 1-Phosphatidylinositol 3-kinase | Inhibitors | Experimental design | Breast | Antitumor activity | Tumors | DNA sequencing | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2016, Volume 375, Issue 3, pp. 209 - 219
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. 989 - 998
Journal Article
Drugs, ISSN 0012-6667, 2015, Volume 75, Issue 5, pp. 543 - 551
Palbociclib (Ibrance(A (R))) is an oral, reversible, selective, small-molecule inhibitor of cyclin-dependent kinases (CDK) 4 and CDK6 developed by Pfizer for... 
PD0332991 | PATHWAYS | TRIAL | DEPENDENT KINASE 4/6 | PD-0332991 | PHARMACOLOGY & PHARMACY | PROLIFERATION | TOXICOLOGY | SCHEDULE | INHIBITOR | PD 0332991 | PHASE-I | Piperazines - administration & dosage | Triazoles - administration & dosage | Triazoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Drugs, Investigational - adverse effects | United States | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drugs, Investigational - therapeutic use | Neoplasm Recurrence, Local - drug therapy | Pyridines - pharmacokinetics | Antineoplastic Agents - therapeutic use | Drug Approval | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Neoplasm Recurrence, Local - pathology | Nitriles - administration & dosage | Aromatase Inhibitors - adverse effects | Pyridines - adverse effects | Drug Interactions | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Cyclin-Dependent Kinases - antagonists & inhibitors | Piperazines - pharmacokinetics | Aromatase Inhibitors - therapeutic use | United States Food and Drug Administration | Pyridines - therapeutic use | Triazoles - therapeutic use | Aromatase Inhibitors - administration & dosage | Protein Kinase Inhibitors - pharmacokinetics | Pyridines - administration & dosage | Neoplasm Recurrence, Local - prevention & control | Clinical Trials as Topic | Piperazines - therapeutic use | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Breast Neoplasms - prevention & control | Protein Kinase Inhibitors - administration & dosage | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Drugs, Investigational - administration & dosage | Neoplasm Staging | Nitriles - adverse effects | Nitriles - therapeutic use | Clinical trials | Care and treatment | Usage | Risk factors | Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2013, Volume 31, Issue 17, pp. 2128 - 2135
Journal Article
Drugs, ISSN 0012-6667, 05/2017, Volume 77, Issue 7, pp. 799 - 807
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2009, Volume 361, Issue 8, pp. 766 - 776
This study of adjuvant hormonal therapy in postmenopausal women with hormone-receptor–positive early breast cancer showed that disease-free survival was... 
SURVIVAL | MEDICINE, GENERAL & INTERNAL | EXEMESTANE | CONTINUED TAMOXIFEN | ADJUVANT ENDOCRINE THERAPY | RANDOMIZED-TRIAL | POSTMENOPAUSAL WOMEN | AROMATASE INHIBITORS | ANASTROZOLE | Aromatase Inhibitors - administration & dosage | Triazoles - administration & dosage | Triazoles - adverse effects | Double-Blind Method | Drug Administration Schedule | Follow-Up Studies | Neoplasm Recurrence, Local - prevention & control | Antineoplastic Agents, Hormonal - administration & dosage | Humans | Kaplan-Meier Estimate | Proportional Hazards Models | Fractures, Bone - epidemiology | Breast Neoplasms - drug therapy | Tamoxifen - administration & dosage | Incidence | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Postmenopause | Female | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Nitriles - adverse effects | Women | Care and treatment | Usage | Breast cancer | Tamoxifen | Comparative analysis | Health aspects | Drug therapy | Womens health | Cancer therapies | Index Medicus | Abridged Index Medicus | Hormonal | Breast Neoplasms | epidemiology | administration & dosage | Triazoles | Nitriles | Adjuvant | drug therapy | Antineoplastic Agents | Local | prevention & control | Aromatase Inhibitors | Chemotherapy | Fractures | adverse effects | Bone | Neoplasm Recurrence | Cancer and Oncology | Kaplan-Meiers Estimate | Cancer och onkologi
Journal Article